MARKET

ALPN

ALPN

Alpine Immune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.80
+0.21
+2.19%
After Hours: 12.50 +2.7 +27.55% 19:56 09/21 EDT
OPEN
9.71
PREV CLOSE
9.59
HIGH
9.99
LOW
9.70
VOLUME
146.16K
TURNOVER
--
52 WEEK HIGH
16.37
52 WEEK LOW
7.21
MARKET CAP
234.37M
P/E (TTM)
-6.5896
1D
5D
1M
3M
1Y
5Y
Insider Sell: Alpine Immune Sciences
MT Newswires · 11h ago
Insider Buy: Alpine Immune Sciences
MT Newswires · 11h ago
Alpine Immune Sciences Earnings Perspective: Return On Capital Employed
Alpine Immune Sciences (NASDAQ:ALPN) brought in sales totaling $7.19 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 2.31%, resulting in a loss of $10.73 million.
Benzinga · 13h ago
BRIEF-Alpine Immune Sciences Reports $91 Mln Private Placement
reuters.com · 6d ago
Alpine Immune Sciences Announces $91M Private Placement
alpn
Benzinga · 6d ago
Alpine Immune Sciences Announced $91 Million Securities Purchase Deal; Shares Climb
MT Newswires · 6d ago
Alpine Immune Sciences Announces Participation in September Investor Conferences
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that members of its management team will present at the ...
Business Wire · 09/07 20:05
Broker Revenue Forecasts For Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Are Surging Higher
Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) shareholders will have a reason to smile today, with the analysts making...
Simply Wall St. · 08/18 10:04
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ALPN. Analyze the recent business situations of Alpine Immune through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ALPN stock price target is 20.00 with a high estimate of 22.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 59
Institutional Holdings: 14.57M
% Owned: 60.93%
Shares Outstanding: 23.91M
TypeInstitutionsShares
Increased
8
758.65K
New
15
460.92K
Decreased
14
642.27K
Sold Out
16
1.11M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.43%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Chairman/Chief Executive Officer/Chief Compliance Officer/Executive Director
Mitchell Gold
President
Stanford Peng
Chief Financial Officer/Senior Vice President/Secretary
Paul Rickey
Director
Jay Venkatesan
Independent Director
Robert Conway
Independent Director
Xiangmin Cui
Independent Director
Natasha Hernday
Independent Director
Christopher Peetz
Independent Director
Peter Thompson
Independent Director
James Topper
No Data
About ALPN
Alpine Immune Sciences, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The Company's scientific platform uses a directed evolution process to convert native immune system proteins from the immunoglobulin super family (IgSF) into multi-targeted therapeutics capable of modulating the human immune system. Its product candidates include ALPN-101, ALPN-202 and ALPN-303. ALPN-101 is a dual inducible T cell costimulator (ICOS) and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Its oncology program is ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. ALPN-303 is a dual B-cell cytokine antagonist for the treatment of B-cell mediated diseases.

Webull offers kinds of Alpine Immune Sciences Inc stock information, including NASDAQ:ALPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALPN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALPN stock methods without spending real money on the virtual paper trading platform.